Intravenous to Subcutaneous Drug Repositioning Market Size, Share & Trends Analysis Report By Product (Devices, Drugs), By Therapeutic Indication (Cardiology, Oncology, Pulmonary Arterial Hypertension, Hematology, Others), By End User (Hospitals & Clinics, Research Facilities, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Intravenous to Subcutaneous Drug Repositioning Market Size

The global intravenous to subcutaneous drug repositioning market size was valued at USD 35.87 billion in 2025 and is projected to grow from USD 38.57 billion in 2026 to USD 68.94 billion by 2034, registering a CAGR of 7.53% during the forecast period from 2026 to 2034. North America dominated the intravenous to subcutaneous drug repositioning market with a market share of 42.5% in 2025.

The intravenous to subcutaneous drug repositioning market is evolving through a strategic shift toward patient-centric delivery and healthcare system efficiency. Advances in formulation science are enabling high-dose biologics to transition into subcutaneous formats without compromising therapeutic outcomes, expanding the scope of eligible drugs. The intravenous to subcutaneous drug repositioning market is being shaped by payer-driven site of care optimization and increasing pressure on infusion infrastructure. At the same time, integrated drug device combinations are redefining competitive positioning. Challenges around bioequivalence and stability remain critical barriers. Growth opportunities emerge from lifecycle extension strategies and the rapid expansion of home-based specialty care, which is transforming how complex therapies are accessed and administered globally.

By Product

The drugs segment is expected to register a CAGR of 8.45% during the forecast period, as pharmaceutical companies increasingly prioritize reformulating existing intravenous therapies into subcutaneous formats to enhance patient convenience and adherence. Within this segment, cancer drugs lead the transition due to the high volume of oncology infusions and the need to reduce hospital burden, followed by immunoglobulin G and blood factors, where home-based administration significantly improves quality of life. Antibiotics and specialized therapies such as Remodulin are also witnessing repositioning as subcutaneous delivery enables continuous dosing and better pharmacokinetic control. The growing acceptance of biologics and advancements in formulation technologies are accelerating the shift toward drug-based repositioning.

The devices segment is expected to register a CAGR of 8.12% during the forecast period, as the shift toward subcutaneous drug delivery increasingly depends on advanced delivery systems that ensure precision, safety, and patient convenience. Within this segment, wearable subcutaneous injectors are gaining strong traction due to their ability to deliver large-volume biologics over extended durations without requiring clinical supervision, making them highly suitable for home-based care. Wearable subcutaneous infusers are also expanding in adoption, particularly for therapies that require continuous or controlled dosing, such as chronic and rare disease treatments. The growth of this segment is driven by rising demand for self-administration, technological advancements in smart and connected devices, and the need to reduce hospital visits while maintaining therapeutic efficacy.

Request Customizationto receive a tailored report.

By Therapeutic Indication

Oncology dominated the therapeutic indication segment with a share of 31.23%, growing at a CAGR of 8.67% during the forecast period due to the extensive use of intravenous chemotherapy and monoclonal antibodies that are increasingly being reformulated into subcutaneous injections. The dominance is driven by the high global cancer burden and the need to optimize treatment delivery in outpatient and home care settings. Subcutaneous oncology drugs reduce chair time in infusion centers and improve patient throughput, which is critical for overburdened healthcare systems. The rapid development of targeted therapies and biologics further supports this transition as companies seek lifecycle extension strategies for blockbuster oncology drugs.

By End User

Hospitals and clinics dominated the intravenous to subcutaneous drug repositioning market with a share of 56.31% in 2025 as they remain the primary centers for initiating and managing complex therapies, especially during the early stages of drug repositioning adoption. These settings provide the infrastructure, trained professionals, and monitoring capabilities required for transitioning patients from intravenous to subcutaneous regimens.

The research facilities segment is expected to grow at a CAGR of 8.67% during the forecast period, as they play a crucial role in clinical trials, formulation development, and validation of subcutaneous delivery technologies. The increasing number of studies focused on improving bioavailability and patient-centric delivery systems is driving growth in research-oriented end users.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America: Market Leadership Driven by Rapid Biologic Innovation and Regulatory Expansion

The North America intravenous to subcutaneous drug repositioning market accounted for a 43.12% share in 2025, driven by the continuous expansion of biologics and regulatory approvals that support alternative delivery routes. In 2025, the US Food and Drug Administration approved 46 novel drugs, including a significant proportion of biologics, many of which are suitable for reformulation into subcutaneous formats. This creates a strong pipeline for lifecycle management strategies where intravenous therapies are transitioned to subcutaneous delivery. The region also benefits from structured reimbursement pathways that increasingly favor outpatient and home-based treatment models, encouraging pharmaceutical companies to invest in SC conversion programs as a cost optimization strategy rather than only a clinical improvement approach.

The US intravenous-to-subcutaneous drug repositioning market is primarily driven by pharmaceutical companies actively pursuing lifecycle extension of high-revenue intravenous drugs through subcutaneous repositioning. The shift in drug innovation trends shows a focus on high-value, patient-centric therapies rather than volume-based approvals, pushing companies to redesign administration routes for competitive differentiation. Many blockbuster oncology and immunology drugs are approaching patent cliffs and converting them into subcutaneous formulations allows companies to retain market exclusivity while improving patient convenience. This strategic commercialization approach makes the US a key hub for IV to SC transitions.

The Canada intravenous to subcutaneous drug repositioning market growth is influenced by its healthcare system’s increasing emphasis on decentralization and reduction of hospital dependency. Provincial health systems are promoting community-based infusion alternatives and home care programs to manage capacity constraints in urban hospitals. This creates a strong demand for subcutaneous alternatives that can be administered outside acute care settings. The focus is on convenience and reducing system-level costs associated with prolonged infusion chair usage, making IV to SC repositioning a practical solution aligned with national healthcare efficiency goals.

Unlock Regional Insightsto access country-level data, & regional trends.

Latin America: Fastest Growth Driven by Expanding Access to Specialty Therapies

The Latin America intravenous to subcutaneous drug repositioning is expected to register the fastest growth with a CAGR of 9.53% during the forecast period due to improving access to specialty therapies, particularly biologics that were previously limited to tertiary care centers. As governments and healthcare systems expand coverage for advanced treatments, there is a parallel need to simplify administration methods. Subcutaneous delivery reduces the dependency on specialized infusion infrastructure, which remains uneven across the region. This makes IV to SC repositioning a key enabler for scaling access to high-value therapies across semi-urban and rural populations.

The Brazil intravenous to subcutaneous drug repositioning market is driven by efforts to optimize its public healthcare system and reduce the burden on hospital-based infusion services. The government is increasingly focused on cost containment and operational efficiency within SUS, encouraging therapies that can shift treatment away from inpatient settings. At the same time, domestic pharmaceutical manufacturing initiatives are supporting local production of biologics and biosimilars, creating opportunities to develop subcutaneous formulations tailored to national demand. This combination of policy direction and manufacturing capability is accelerating adoption.

The Argentina intravenous to subcutaneous drug repositioning market growth is shaped by strong cost sensitivity within its healthcare system and the need to maintain continuity of care despite economic fluctuations. Subcutaneous drug delivery reduces hospitalization and infrastructure costs, making it an attractive alternative for both providers and patients. Healthcare institutions are increasingly adopting treatment models that minimize resource-intensive infusion procedures while ensuring consistent dosing schedules. This makes IV to SC repositioning particularly relevant in maintaining long-term therapy adherence in a constrained economic environment.

Competitive Landscape

The intravenous to subcutaneous drug repositioning market is moderately fragmented, characterized by the presence of large multinational pharmaceutical companies alongside niche biotech firms and drug delivery technology providers. Key players operate alongside regional and specialized participants, reflecting a competitive but not highly consolidated structure. Established players primarily compete on advanced formulation capabilities, strong clinical trial pipelines, regulatory expertise, and lifecycle management strategies aimed at extending product exclusivity through IV to SC transitions. In contrast, emerging players focus on innovation in delivery technologies such as wearable injectors, cost-efficient reformulation techniques, and strategic collaborations with device manufacturers to enable patient-centric administration. The market also witnesses increasing partnerships between pharma and device companies to enhance usability and expand home care treatment options, intensifying competition across the value chain.

List of Key and Emerging Players in Intravenous to Subcutaneous Drug Repositioning Market